DCIS

There is a lack of data on the risk of invasive breast cancer with HRT after ductal carcinoma in situ (DCIS) to allow evidence-based recommendations to be concluded.

Guidance is therefore to advise this group in the same way as women with invasive breast cancer and lifestyle and non-hormonal alternatives should be offered first line.

HRT may in exceptional cases be offered to women with a history of DCIS where symptoms are severe and non-hormonal modifications are not effective. This should be done after discussion with the woman, oncology specialist and her breast/oncology team.